Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly

A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

NCT04139915•Restorbio Inc.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Clinically Symptomatic Respiratory Illness

Interventions

Dactolisib

Placebo

Key Dates

Start Date

October 21, 2019

Primary Completion Date

November 15, 2019

Completion Date

November 15, 2019

Last Updated

November 22, 2019

Sponsors

Lead Sponsor

Restorbio Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions